Analgesic effect of central relaxin receptor activation on persistent inflammatory pain in mice: behavioral and neurochemical data.
Abboud. Cynthia C; Brochoire. Louison L; Drouet. Adèle A; Hossain. M Akhter MA; Hleihel. Walid W; Gundlach. Andrew L AL; Landry. Marc M
Key Findings
- B7-33 and the related peptide H2‑relaxin quickly lowered mechanical and thermal pain sensitivity in inflamed mouse paws when delivered into the brain ventricles.
- The pain‑relieving effect was short‑lived (about 30 minutes) and could be blocked for touch‑pain by a specific RXFP1 antagonist.
- RXFP1 receptors are present on excitatory neurons in brain areas that process pain, and relaxin‑producing neurons project to these regions.
Practical Outcomes
- The study shows that activating the brain's relaxin receptor can produce brief analgesia, suggesting a new pain‑modulating pathway. However, the method (direct brain injection) isn’t feasible for humans, so it’s not an actionable protocol for biohackers yet. Future work might focus on developing peripheral or orally active relaxin‑mimetic compounds that could tap into this system.
Summary
In mice, injecting the peptide B7-33 (which activates the brain's relaxin receptor) into the fluid-filled spaces of the brain temporarily reduced pain from inflammation, making the paw less sensitive to touch and heat. The effect lasted about 30 minutes and was blocked for touch pain when a receptor blocker was also given.
Abstract
The relaxin peptide signaling system is involved in diverse physiological processes, but its possible roles in the brain, including nociception, are largely unexplored. In light of abundant expression of relaxin receptor (RXFP1) mRNA/protein in brain regions involved in pain processing, we investigated the effects of central RXFP1 activation on nociceptive behavior in a mouse model of inflammatory pain and examined the neurochemical phenotype and connectivity of relaxin and RXFP1 mRNA-positive neurons. Mice were injected with Complete Freund Adjuvant (CFA) into a hind paw. After 4 days, the RXFP1 agonist peptides, H2-relaxin or B7-33, ± the RXFP1 antagonist, B-R13/17K-H2, were injected into the lateral cerebral ventricle, and mechanical and thermal sensitivity were assessed at 30 to 120 minutes. Relaxin and RXFP1 mRNA in excitatory and inhibitory neurons were examined using multiplex, fluorescent in situ hybridization. Relaxin-containing neurons were detected using immunohistochemistry and their projections assessed using fluorogold retrograde tract-tracing. Both H2-relaxin and B7-33 produced a strong, but transient, reduction in mechanical and thermal sensitivity of the CFA-injected hind paw alone, at 30 minutes postinjection. Notably, coinjection of B-R13/17K-H2 blocked mechanical, but not thermal, analgesia. In the claustrum, cingulate cortex, and subiculum, RXFP1 mRNA was expressed in excitatory neurons. Relaxin immunoreactivity was detected in neurons in forebrain and midbrain areas involved in pain processing and sending projections to the RXFP1-rich, claustrum and cingulate cortex. No changes were detected in CFA mice. Our study identified a previously unexplored peptidergic system that can control pain processing in the brain and produce analgesia.
Study Information
pubmed
2021
2021-06-16T00:00:00.000Z
10.1097/pr9.0000000000000937